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Background-—Risk assessment is the cornerstone for atherosclerotic cardiovascular disease (ASCVD) treatment decisions. The
Pooled Cohort Equations (PCE) have not been validated in disaggregated Asian or Hispanic populations, who have heterogeneous
cardiovascular risk and outcomes.
Methods and Results-—We used electronic health record data from adults aged 40 to 79 years from a community-based, outpatient
healthcare system in northern California between January 1, 2006 and December 31, 2015, without ASCVD and not on statins. We
examined the calibration and discrimination of the PCE and recalibrated the equations for disaggregated race/ethnic subgroups. The
cohort included 231 622 adults with a mean age of 53.1 (SD 9.7) years and 54.3% women. There were 56 130 Asian (Chinese, Asian
Indian, Filipino, Japanese, Vietnamese, and other Asian) and 19 760 Hispanic (Mexican, Puerto Rican, and other Hispanic) patients.
There were 2703 events (332 and 189 in Asian and Hispanic patients, respectively) during an average of 3.9 (SD 1.5) years of follow-
up. The PCE overestimated risk for NHWs, African Americans, Asians, and Hispanics by 20% to 60%. The extent of overestimation of
ASCVD risk varied by disaggregated racial/ethnic subgroups, with a predicted-to-observed ratio of ASCVD events ranging from 1.1
for Puerto Rican patients to 1.9 for Chinese patients. The PCE had adequate discrimination, although it varied signiﬁcantly by race/
ethnic subgroups (C-indices 0.66–0.83). Recalibration of the PCE did not signiﬁcantly improve its performance.
Conclusions-—Using electronic health record data from a large, real-world population, we found that the PCE generally
overestimated ASCVD risk, with marked heterogeneity by disaggregated Asian and Hispanic subgroups. ( J Am Heart Assoc.
2019;8:e011874. DOI: 10.1161/JAHA.118.011874.)
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H ispanic and Asian populations are the 2 most rapidlygrowing minority groups in the United States and are
expected to double in size by 2050 to 110 and 30 million,
respectively.1,2 Despite this projected growth, there is little
data on the cardiovascular health of these groups.3–7 When
Hispanic and Asian individuals are studied, they are often
aggregated into 1 group, masking important differences
between distinct subpopulations. Prior work has documented
marked heterogeneity in cardiovascular disease risk and
mortality patterns in disaggregated Hispanic and Asian
subgroups.8–15
Risk assessment is the foundation for guiding atheroscle-
rotic cardiovascular disease (ASCVD) treatment decisions,
especially for initiation of lipid-lowering therapy. The 2013
prevention guidelines released by the American Heart Associ-
ation (AHA) and the American College of Cardiology (ACC)
recommended statin therapy for primary prevention based on
10-year estimated ASCVD risk.16 The recent 2018 update to
these guidelines similarly relies on the Pooled Cohort Equations
(PCE) to guide recommendations for risk stratiﬁcation and
statin treatment decisions.17 This update highlights the uncer-
tainty of the PCE performance in diverse race/ethnic groups
such as Asians and Hispanics since the PCE was derived from
non-Hispanic white (NHW) and African American populations.
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The PCE computation requires sex, age, race (African Ameri-
can/NHW/other), total and high-density lipoprotein (HDL)
cholesterol, systolic blood pressure, blood pressure treatment
status, smoking status, and diabetes mellitus status.2
Whether the PCE adequately identiﬁes risk for diverse
populations remains controversial and several recent analyses
of calibration and discrimination of the risk scores have
yielded mixed results.18–21 The ACC/AHA Work Group, which
developed the risk estimator algorithm, acknowledges that it
was designed for use only in men and women of NHW or
African American descent, and that the risk estimator may not
accurately predict risk in other racial/ethnic groups,2 such as
Hispanic and Asian populations, which together make up over
a quarter of the US population.1 Speciﬁcally, the Pooled
Cohort Equations may overestimate risk in Mexican Ameri-
cans and East Asians (Japanese, Korean, and Vietnamese) and
underestimate risk in Puerto Ricans and South Asians.2,16
However, this assumption has not been validated and the
extent of over- or underestimation of ASCVD risk in speciﬁc
populations remains unknown.
Methods and Results
The data used in this study will not be made publicly available.
Study Sample
The study sample was selected from electronic health records
(EHR) of adults aged between 40 and 79 years in a large,
community-based outpatient healthcare system in northern
California between January 1, 2006 and December 31, 2015.
To minimize missing information or incomplete event
ascertainment, included patients were required to have at
least 2 outpatient visits that were at least 1 year apart. The
index date was deﬁned as the ﬁrst available cholesterol or
blood pressure measurement date after an outpatient visit.
Patients with pre-existing ASCVD, atrial ﬁbrillation, or heart
failure identiﬁed by the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) coding
scheme were excluded. As per the PCE derivation guideline,
patients with atrial ﬁbrillation at baseline were excluded
because of the strong relationship between atrial ﬁbrillation
and stroke and the documented need for risk reducing
therapies.2
We also excluded patients without complete information
on cardiovascular risk factors necessary for ASCVD risk
calculation or those who were on statins or other lipid-
lowering therapies at baseline.
Race/ethnicity was self-reported (83.2%) or inferred
(16.8%) based on the Social Security Record database as
previously described.22 The study sample included NHWs,
African Americans, Asians, and Hispanics. Asians were
disaggregated into Chinese, Asian Indian, Filipino, Japanese,
Korean, Vietnamese, and other Asians. Based on US Census
categories, Hispanics were disaggregated into Mexican,
Puerto Rican, Cuban, and other Hispanics. Because of small
sample size (n=223), Cubans were combined with other
Hispanics.
ASCVD Events
In line with the ACC/AHA Work Group guidelines, we deﬁned
ASCVD events as the ﬁrst fatal or non-fatal acute myocardial
infarction or stroke.2 Acute myocardial infarction was deﬁned
by ICD-9-CM codes 410.x0 and 410.x1.20,23 Non-fatal
incident ischemic and hemorrhagic stroke events were
deﬁned based on ICD-9-CM codes 433.x1, 434.x1 or
436.0.20,24 Coronary heart disease followed by death within
a year, or fatal or non-fatal ischemic or hemorrhagic stroke
followed by death within a year were identiﬁed as ASCVD
deaths. Death information was retrieved from the EHR and
Social Security records.
Prediction of ASCVD Risk Based on Pooled
Cohort Equation and Recalibration
The 5-year ASCVD predicted risk was calculated for adults
between ages 40 to 79 using the published parameter
estimates from the PCE.2,20 We used the parameters devel-
oped for NHWs to estimate predicted values for Asian and
Hispanic populations. The 5-year predicted risk values were
adjusted to reﬂect varying follow-up time, assuming propor-
tional hazard, which was validated in our data (global test of
proportional v2 (11)=0.115 and plotting of Schoenfeld
Clinical Perspective
What Is New?
• We found that the Pooled Cohort Equations generally
overestimated risk among disaggregated Hispanic and Asian
patients but that the degree of overestimation varied
signiﬁcantly by racial/ethnic subgroup.
What Are the Clinical Implications?
• It is reasonable to use the Pooled Cohort Equations among
Hispanic and Asian patients since its performance is
comparable with that of non-Hispanic whites.
• However, caution must be used in interpreting results by
disaggregated patient racial/ethnic subgroups, since the
degree of risk overestimation is different.
• Electronic health record data offer great promise in
developing personalized, risk-speciﬁc cardiovascular risk
prediction models.
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residuals where slopes for all covariates were nearly ﬂat).
Patients were censored at the time of the ﬁrst event.
The PCE was then recalibrated from the study population
using a Cox proportional hazard model with the same set of
covariates and speciﬁcations as the PCE, and using 10-fold
cross-validation. We randomly partitioned the sample into 10
groups, and used a 9/10th (training set) to estimate
coefﬁcients and, by applying the coefﬁcients to the remaining
1/10th (test set), computed predicted risk for the test set.
After repeating this procedure with the other 9 training sets
and 9 test sets, all the patients in the sample were assigned
with a predicted 5-year risk values derived from the cross-
validation. Since the PCE is deﬁned for NHWs and African
Americans, we used the PCE speciﬁcations for NHWs in
recalibrating Asian and Hispanic subgroups. Since there is
signiﬁcant racial admixture among Hispanics, we also per-
formed a sensitivity analysis using the PCE speciﬁcations for
African Americans in recalibrating Hispanic subgroups.
Calibration and Discrimination of the PCE
We calculated the predicted incidence of ASCVD during the
follow-up period based on the PCE and compared those with
the observed events and drew statistical inference based on
the paired t-test. Patients were then categorized into 4 groups
according to their PCE 10-year predicted ASCVD risk which
was computed using parameter estimates from the PCE: <5%,
≥5 and <7.5%, ≥7.5 and <10%, and ≥10%. For each risk
subgroup, we calculated and plotted predicted ASCVD
incidence during the follow-up period based on the PCE and
compared those to the observed events to evaluate extent of
over- or underestimation. The Hosmer-Lemeshow v2 statistic
was used to estimate the calibration of the PCE estimator.
C-indices were computed for predicted risk based on the
PCE and recalibrated equations, respectively, for each racial/
ethnic group, and statistical difference was calculated by
differences in the C-indices and 95% CI derived from 1000
bootstrapped samples. All analyses were performed using
Stata statistical software version 13.1.
This study was approved by the Stanford Institutional
Review Board for human subjects, which waived the need for
patient consent.
The study sample assembly is shown in Figure 1. We
restricted the analysis to patients aged between 40 and
79 years with at least 2 outpatient visits that were at least
1 year apart (n=273 585). We excluded 14 179 patients with
pre-existing ASCVD, atrial ﬁbrillation, or heart failure and
27 784 participants with missing risk factor information,
missing race/ethnicity, or on lipid-lowering therapy at base-
line. The ﬁnal study population included a total of 231 622
patients with a mean follow-up of 3.9 years (SD 1.5).
The study population (Table 1) had a mean age of 53.1 (SD
9.7) and 54.3% were women. There were 56 130 Asian and
19 760 Hispanic patients. There was signiﬁcant heterogeneity
in ASCVD risk factors by disaggregated subgroup. Asian
Indians (mean age 47.7) were signiﬁcantly younger than
NHWs and other Asian subgroups in the sample. Chinese
patients had a diabetes mellitus prevalence of 6.5% compared
with 17.6% for Filipinos. Within Hispanic subgroups, Mexicans
had the highest prevalence of diabetes mellitus (16.5%), and
Age 40-79 (with at least two visits 
in 2006-2010) 
N=273,585
Excluded
• Lipid-lowering therapy at baseline (n=7,469)
• Missing total or HDL cholesterol (n=7,338)
• Missing ambulatory systolic blood pressure (n=7,223)
• Missing smoking status (n=1,088)
• Race/ethnicity unknown or other than NHW, African-
American, Asian, or Hispanic (n=4,666)
Study Cohort
N=231,622
Excluded: 
• Existing cardiovascular disease: coronary artery 
disease, myocardial infarction, stroke, atrial fibrillation, 
or heart failure (n=14,179)
Age 40-79 with no CVD
N=259,406
Figure 1. Study cohort. *Pre-existing cardiovascular disease was deﬁned by the following International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes: Atrial ﬁbrillation: 427.31;
heart failure: 428*; coronary artery disease: 411*, 413*, 414*; myocardial infarction; 410*; and stroke:
430–434*, 436*. ASCVD indicates atherosclerotic cardiovascular disease; CVD, cardiovascular disease;
HDL, high-density lipoprotein cholesterol; NHW, non-Hispanic white.
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Puerto Ricans had the highest prevalence of smoking (8.1%)
as compared with other Hispanics and NHWs.
There were a total 2703 events (332 and 189 in Asian and
Hispanic patients, respectively) during the study period. The
ﬁrst occurrence of ASCVD by disaggregated race/ethnic
group and event type is shown in Table S1. Asians and
Hispanics had an aggregated event rate of 0.9% and 1.3%,
respectively. These rates differed substantially by subgroup.
The highest event rates were observed among Vietnamese
(1.2%), Filipino (1.2%), and Puerto Rican patients (1.5%).
The differences between the PCE predicted and observed
event rates by race/ethnicity are shown in Table 2. Overall,
the PCE overestimated risk for NHWs, African Americans,
Asians, and Hispanics by 20% to 60%. However, the extent of
overestimation of ASCVD risk varied by disaggregated racial/
ethnic subgroups, with a predicted-to-observed ratio of
ASCVD events ranging from 1.1 for Puerto Rican patients to
1.9 for Chinese patients. The PCE slightly underestimated risk
among Vietnamese patients, with an predicted-to-observed
ratio of 0.9, although this difference was not statistically
signiﬁcant (P=0.655).
Observed versus predicted ASCVD risk by race/ethnicity
and pre-speciﬁed 10-year risk categories is shown in Figure 2.
Observed versus predicted ASCVD risk differed signiﬁcantly
within all race/ethnic groups. The PCE generally overesti-
mated risk across race/ethnic groups. However, there was
signiﬁcant heterogeneity within disaggregated Hispanic and
Asian subgroups across risk categories. Most of the overes-
timation of risk occurred in the higher risk categories. The
PCE was better calibrated for Korean (v2=4.5, P=0.107),
Puerto Rican (v2=1.9, P=0.40), and other Hispanic patients
(v2=5.9, P=0.1) (Table S2).
The discrimination of predicted values from the PCE and
recalibrated PCE by race/ethnicity is shown in Table 3. The C-
index for NHWs was 0.77, 95% CI (0.76–0.78) and 0.74, 95%
CI (0.66–0.81) for African Americans. Overall, the PCE had
adequate discrimination for Hispanics and Asians with an
overall C-index of 0.78, 95% CI (0.76–0.81) and 0.78; 95% CI
(0.75–0.80), respectively. However, there was marked hetero-
geneity by racial/ethnic subgroup. The C-index ranged from
0.66 in Puerto Rican patients to 0.83 for Korean patients.
Recalibration did not signiﬁcantly improve the performance of
the PCE in the study population. Using speciﬁcations for
African Americans for the PCE recalibration among Hispanic
subgroups, similarly failed to signiﬁcantly improve its perfor-
mance (Table S3).
Table 1. Characteristics of the Study Sample by Race/Ethnicity*
Race/Ethnic
Subgroup n
Follow-Up (y),
Mean (SD)
Age (y),
Mean (SD)
Female
(%)
SBP (mm Hg)
Mean (SD)
On Anti-
Hypertensive
Medication
(%)†
HDL
Cholesterol
(mg/dL),
Mean (SD)
Total
Cholesterol,
mg/dL, Mean
(SD)
Type 2
Diabetes
mellitus (%)
Current
Smoker
(%)
Overall 231 622 3.9 (1.5) 53.1 (9.7) 54.3% 123.0 (16.5) 3.8% 56.4 (16.5) 198.1 (36.5) 8.3% 5.1%
NHW (ref) 151 615 4 (1.5) 54.3 (9.6) 53.6% 124.1 (16.4) 4.0% 57.5 (16.9) 199.7 (36.7) 6.8% 5.6%
African
American
4117 3.9 (1.5)* 52.4 (9.1)* 56.4% 128.5 (17.0)* 5.9%* 56.9 (16.3) 195.7 (38.1)* 14.8%* 9.6%*
Asian 56 130 3.9 (1.6)* 50.4 (9.5)* 54.9% 119.5 (16.3)* 3.0%* 54.7 (15.4)* 193.7 (35.2)* 10.0%* 3.1%*
Hispanic 19 760 3.8 (1.6)* 51.8 (9.3)* 57.3%* 124.2 (16.4) 4.3% 52.6 (15.1)* 199.0 (37.3) 14.3%* 5.8%
Chinese 23 171 4.0 (1.5) 51.1 (9.6)* 56.7%* 117.8 (16.0)* 2.4%* 56.5 (15.2)* 191.7 (34.0)* 6.5% 2.0%*
Asian Indian 13 815 3.8 (1.6) 47.7 (8.5)* 43.1%* 119.2 (15.5)* 3.0%* 47.9 (13.0)* 190.5 (34.7)* 13.4%* 3.0%*
Filipino 6220 4.0 (1.5)* 52.1 (9.4)* 63.4%* 126.3 (17.1)* 4.7% 55.8 (14.9)* 199.1 (37.7) 17.6%* 5.8%
Japanese 3825 4.1 (1.4) 53.7 (10.2)* 63.4%* 122.3 (16.8)* 2.9%* 62.0 (17.2)* 202.7 (36.0)* 10.4%* 3.0%*
Korean 1793 3.6 (1.6) 49.6 (9.9)* 61.5%* 117.9 (15.6)* 2.6% 57.5 (15.5) 193.8 (34.9)* 8.9%* 5.9%
Vietnamese 2093 3.9 (1.5)* 49.9 (8.4)* 58.4%* 118 (15.5)* 2.8% 56.5 (15.1) 200.9 (34.4) 7.6% 3.7%*
Other Asian 5213 3.4 (1.7) 50.8 (9.4)* 57.7%* 119.1 (16.5)* 3.2% 56.4 (15.9)* 195.4 (35.9)* 8.1%* 3.6%*
Mexican 8655 3.9 (1.5)* 51.6 (9.3)* 57.5%* 125.0 (16.4)* 4.3% 51.3 (14.6)* 199.2 (37.5) 16.5%* 5.7%
Puerto Rican 457 4.0 (1.5)* 51.4 (9.3)* 58.9%* 122.3 (15.3)* 5.0% 53.2 (14.8)* 199.1 (37.0) 13.3%* 8.1%
Other
Hispanic
10 643 3.6 (1.7) 52.0 (9.4)* 57.1%* 123.5 (16.5) 4.2% 53.6 (15.5)* 198.9 (37.1) 12.5%* 5.7%
HDL indicates high-density lipoprotein; NHW, non-Hispanic white; SBP, systolic blood pressure.
*Difference between NHW and each subgroup is statistically signiﬁcant at P<0.001 for all variables in BOLD. Statistical testing was based on t test for continuous variables and Fisher
exact test for dichotomous variables.
†On antihypertensive medication when blood pressure was measured (if index blood pressure measure date falls into [Prescription start date 7 days, prescription end date +30 days]).
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Discussion
Using EHR data from a large healthcare system in northern
California, we found that the PCE generally overestimated
ASCVD risk in a diverse cohort of patients. However, we
document signiﬁcant heterogeneity in the extent of risk
overestimation among disaggregated Asian and Hispanic
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Figure 2. Comparison of 5-year observed vs predicted atherosclerotic cardiovascular risk by race/ethnicity and 10-year PCE
risk categories. A, Overall population by major race/ethnic subgroups, (B) Asian subgroups, (C) Hispanic subgroups. ASCVD
indicates atherosclerotic cardiovascular disease; PCE, Pooled Cohort Equation.
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subgroups, populations who were not included in the original
PCE derivation cohorts. The PCE was better calibrated for
Korean and Puerto Rican subgroups. Discrimination also
differed by subgroups and recalibration failed to signiﬁcantly
improve the PCE performance across disaggregated sub-
groups.
ASCVD remains the leading cause of death for men and
women in the United States and, importantly, ASCVD is
largely preventable through lifestyle modiﬁcations and ade-
quate risk factor management. Effective prevention requires
an assessment of risk for selection of appropriate interven-
tions. The current risk equations were developed to predict
10-year risk of a ﬁrst ASCVD event, and were derived from 5
large community-based prospective cohorts of US NHW and
African American populations. These risk calculators are
widely used in routine to clinical practice to make decisions
about statins, aspirin, and antihypertensives.2,25,26 Several
large studies have since been conducted to validate the PCE
in real-world populations, with conﬂicting conclusions and
resulting controversy.18,20,27–30 A cohort of Kaiser Perma-
nente northern California members in 2008 to 2013 con-
cluded that the PCE substantially overestimated 5-year risk
across diverse sociodemographic subgroups.28 In a recent
study of the Women’s Health Initiative cohort of post-
menopausal women aged 50 to 79 years, the PCE overesti-
mated ASCVD risk across racial groups, although risks were
better aligned with PCE predictions after inclusion of further
Medicare-adjudicated ASCVD events.27
With these conﬂicting results, a recent study updated the
data used to derive the PCE with newer cohorts and applied
revised statistical models, which reduced risk overestimation
overall and implausible risk estimates in African Americans in
particular, but did not provide revised PCEs for racial groups
other than African American or NHW adults.31 Another study
used a large cohort of primary care patients in New Zealand to
recalibrate the PCE to reﬂect the low risk setting of a high-
income country population, but similarly did not report revised
equations for disaggregated race subgroups.32 Our study is
the ﬁrst to speciﬁcally look at disaggregated Asian and
Hispanic subgroups using a contemporary clinical cohort from
EHR data.
Our ﬁndings have important real-world implications. Unlike
most validation studies, which have relied on data from
longitudinal cohort studies, our study population is strength-
ened by a diverse observational EHR-based patient sample of
disaggregated Asians and Hispanics. This is signiﬁcant
because participants who elect to enroll in longitudinal cohort
studies may be healthier than those enrolled in regular clinical
care.33 We found that data collected in routine clinical
practice that are captured in the EHR can be used for ASCVD
risk prediction, with similar performance to other stud-
ies.20,27,29,34 Although Asian and Hispanic participants were
not considered in the original PCE derivation cohorts, we
found that, when studied in aggregate, the overall perfor-
mance of the equations for these diverse patients was similar
to that of NHWs.
Table 2. Pooled Cohort Equations Predicted vs Observed Rates of Atherosclerotic Cardiovascular Disease by Race/Ethnic
Subgroup
n PCE-Predicted ASCVD Observed ASCVD Predicted-to-Observed Ratio P Value*
All 231 622 1.70% 1.20% 1.5 <0.001
NHW 151 615 1.90% 1.20% 1.5 <0.001
African American 4117 2.10% 1.30% 1.6 <0.001
Asian 56 130 1.40% 0.90% 1.5 <0.001
Hispanic 19 760 1.60% 1.30% 1.2 <0.001
Chinese 23 171 1.40% 0.70% 1.9 <0.001
Asian Indian 13 815 1.20% 0.90% 1.3 <0.001
Filipino 6220 1.70% 1.20% 1.5 <0.001
Japanese 3825 1.90% 1.10% 1.8 <0.001
Korean 1793 1.20% 0.70% 1.6 0.024
Vietnamese 2093 1.10% 1.20% 0.9 0.655
Other Asian 5213 1.20% 1.00% 1.1 0.298
Mexican 8655 1.70% 1.30% 1.3 <0.001
Puerto Rican 457 1.60% 1.50% 1.1 0.887
Other Hispanic 10 643 1.60% 1.30% 1.2 0.024
ASCVD indicates atherosclerotic cardiovascular disease; NHW, non-Hispanic white; PCE, Pooled Cohort Equations.
*Difference between observed and PCE-predicted ASCVD risk of varying follow-up by subgroup based on paired t test.
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Importantly, we found that the PCE showed differences in
calibration and discrimination by disaggregated race/ethnic
subgroups. Disaggregated Asian and Hispanic subgroups
differ signiﬁcantly by cardiovascular risk and out-
comes.8,9,35,36 In fact, the revised cholesterol guidelines note
this marked heterogeneity by race/ethnic groups and now
identify ethnicity as a potential “ASCVD risk enhancer.”17 In
our study, the PCE was better calibrated for Korean and
Puerto Rican patients and had generally adequate discrimi-
nation across race/ethnic subgroups. As seen by differences
in baseline characteristics, it is likely that differences in
clinical disease phenotypes (eg, higher rates of diabetes
mellitus in some subgroups) may impact the performance of
the PCE among these subgroups. Although some Hispanic
subgroups have African ancestry, using the parameters for
African Americans did not improve the PCE's performance
among Hispanics. Notably, recalibration of the PCE failed to
improve discrimination across all groups. This suggests that
novel risk prediction models should consider updated risk
factors and relationships that are not currently present in the
PCE.
Our results should be interpreted in light of several
limitations. Because of low event numbers, some disaggre-
gated racial/ethnic subgroups had to be excluded from the
analysis (Cubans) and were combined with the “other”
category. Importantly, the “other” Hispanic and Asian
subgroups represent heterogeneous populations and our
recalibrated equations thus should not be generalized to
these subgroups. The study sample was comprised of a
diverse population in northern California and may not
reﬂect the general US population. Some racial groups may
have been under- or overrepresented in our study popula-
tion (ie, Mexicans among Hispanics and Chinese Americans
among Asian subgroups) and the small numbers of patients
in some subgroups may have affected our models’ perfor-
mance. Our study population is likely to be insured and of
higher socioeconomic status and therefore our results
cannot be extrapolated to all settings. Our data originate
from the EHR, which has inherent limitations including that
the data are collected for clinical purposes and not for
research.37 Race/ethnicity was self-reported in the majority
of the study sample and inferred in the remainder based on
previously validated methods using name lists to infer
race/ethnic subgroup.22 Such approaches may have led to
misclassiﬁcation of race/ethnicity. Incident ASCVD events
that occurred outside of the health system may not be fully
captured. This underreporting of events may have led to
underestimation of observed event rates, although our
results are well-aligned with other studies.20,28,34 We
attempted to minimize the potential missing information
by requiring that patients have at least 2 outpatient visits
and stayed in the healthcare system for at least 1 year and
by matching EHR records to Social Security Records to
ensure that deaths were appropriately captured.
Future risk prediction models should not only include
Asians and Hispanics, the 2 largest and growing minority
groups in the United States, but also disaggregate by major
subgroups. Our study suggests that information routinely
captured in clinical care may be useful in risk prediction.
Using novel algorithms and continuing to reﬁne the demo-
graphic and clinical variables considered will likely improve
future risk prediction models for diverse populations.
In summary, we used EHR data from a health system in
northern California to validate the PCE for estimating ASCVD
risk among disaggregated Asian and Hispanic patients. We
found that the PCE generally overestimated predicted risk
among this diverse patient cohort, but provided adequate
discrimination. These ﬁndings have important implications for
the use of the EHR-based variables in ASCVD risk prediction
across diverse populations.
Sources of Funding
Dr. Rodriguez received support from the McCormick Faculty
Fellowship from Stanford University School of Medicine and
the National Heart, Lung, and Blood Institute, National
Table 3. Discrimination of PCE and Recalibrated PCE by
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Table S1. ASCVD Incidence by race/ethnicity*. 
*During study period with average follow-up time of 3.9 years
ASCVD = atherosclerotic cardiovascular disease; MI = myocardial infarction; CAD = coronary artery disease
The table shows the incidence of ASCVD events during follow-up. Only the first occurrence of an ASCVD event was counted.
N 
Total 
ASCVD 
Events 
Total 
ASCVD 
MI 
Ischemic 
stroke 
Hemorrhagic 
stroke 
Fatal CAD 
All 231,622 2,703 1.20% 0.39% 0.54% 0.18% 0.06% 
NHW 151,615 1,894 1.20% 0.41% 0.58% 0.18% 0.08% 
African American 4,117 53 1.30% 0.41% 0.80% 0.05% 0.02% 
Asian 56,130 494 0.90% 0.30% 0.37% 0.18% 0.02% 
Hispanic 19,760 262 1.30% 0.43% 0.61% 0.26% 0.04% 
Chinese 23,171 166 0.70% 0.21% 0.34% 0.17% 0.00% 
Indian 13,815 123 0.90% 0.41% 0.29% 0.17% 0.02% 
Filipino 6,220 72 1.20% 0.50% 0.43% 0.13% 0.10% 
Japanese 3,825 41 1.10% 0.24% 0.58% 0.24% 0.03% 
Korean 1793 13 0.70% 0.17% 0.33% 0.22% 0.00% 
Vietnamese 2,093 26 1.20% 0.43% 0.57% 0.19% 0.05% 
Other Asian 5,213 53 1.00% 0.29% 0.46% 0.25% 0.02% 
Mexican 8,655 115 1.30% 0.40% 0.70% 0.22% 0.00% 
Puerto Rican 457 7 1.50% 0.44% 0.66% 0.44% 0.00% 
Other Hispanic 10,643 140 1.30% 0.44% 0.53% 0.28% 0.07% 
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Table S2. Observed and PCE Predicted ASCVD Risk by PCE-predicted 10-year Risk Category and Race/ethnicity.  
 
  
PCE 10yr risk 
category Observed 
PCE predicted 
5yr ASCVD Ch-sq P-Val 
ALL <5% 0.4% 0.5%     
  <7.5% 1.4% 1.9%     
  <10% 1.6% 2.8%     
  10+% 4.0% 6.4% 490.5 <0.001 
NHW <5% 0.5% 0.6%     
  <7.5% 1.4% 1.9%     
  <10% 1.7% 2.8%     
  10+% 4.0% 6.4% 351.4 <0.001 
African American <5% 0.4% 0.7%     
  <7.5% 1.5% 1.9%     
  <10% 0.9% 2.9%     
  10+% 3.5% 5.8% 14.9 <0.001 
Asian <5% 0.4% 0.5%     
  <7.5% 1.2% 1.9%     
  <10% 1.1% 2.7%     
  10+% 3.7% 6.6% 120.0 <0.001 
Hispanic <5% 0.5% 0.5%     
  <7.5% 1.7% 1.9%     
  <10% 1.9% 2.6%     
  10+% 4.7% 6.5% 18.0 <0.001 
Chinese <5% 0.3% 0.5%     
  <7.5% 1.0% 2.0%     
  <10% 0.9% 2.8%     
  10+% 3.2% 6.7% 78.6 <0.001 
Asian Indian <5% 0.4% 0.5%     
  <7.5% 1.5% 1.9%     
  <10% 1.1% 2.7%     
  10+% 4.6% 6.4% 13.1 <0.001 
Filipino <5% 0.5% 0.5%     
  <7.5% 1.7% 1.9%     
D
ow
nloaded from
 http://ahajournals.org by on July 19, 2019
  <10% 1.8% 2.8%     
  10+% 3.8% 6.6% 14.3 <0.001 
Japanese <5% 0.4% 0.5%     
  <7.5% 0.6% 2.0%     
  <10% 1.0% 2.9%     
  10+% 3.9% 7.4% 16.5 <0.001 
Korean <5% 0.3% 0.4%     
  <7.5% 0.9% 1.7%     
  <10% 1.9% 2.5%     
  10+% 3.0% 6.5% 4.5 0.107 
Vietnamese <5% 1.0% 0.5%     
  <7.5% 0.7% 2.0%     
  <10% 1.1% 2.7%     
  10+% 4.6% 6.2% 12.0 0.002 
Other Asian <5% 0.5% 0.4%     
  <7.5% 1.1% 1.7%     
  <10% 1.5% 2.5%     
  10+% 4.0% 5.5% 6.7 0.036 
Mexican <5% 0.5% 0.5%     
  <7.5% 1.7% 1.9%     
  <10% 1.9% 2.8%     
  10+% 4.4% 6.7% 12.8 0.002 
Puerto Rican <5% 0.9% 0.5%     
  <7.5% 0.0% 2.2%     
  <10% 4.3% 3.1%     
  10+% 4.8% 6.5% 1.9 0.4 
Other Hispanic <5% 0.5% 0.5%     
  <7.5% 1.8% 1.8%     
  <10% 1.8% 2.4%     
  10+% 4.9% 6.3% 5.9 0.1 
 
 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on July 19, 2019
Table S3. Pooled Cohort Equation Discrimination using African American Parameters among Hispanics. 
 
Race/Ethnic 
Subgroup 
PCE Recalibrated PCE 
p-value for 
comparison 
  C-index (95% CI) C-index (95% CI)  
All Hispanics 0.75 (0.71, 0.78) 0.78 (0.75, 0.80) 0.043 
Mexican  0.74 (0.69, 0.80) 0.78 (0.73, 0.82) 0.095 
Puerto Rican  0.67 (0.41, 0.88) 0.67 (0.43, 0.89) 0.960 
Other Hispanic 0.76 (0.71, 0.80) 0.78 (0.74, 0.82) 0.160 
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